factor

(redirected from Leukemia inhibitory factor)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Factor

A financial institution that buys a firm's accounts receivable and collects the accounts.

Factor

A third party that buys a firm's accounts receivable. If a firm is not confident in its ability to collect on its credit sales, it may sell the right to receive payment to the factor at a discount. The factor then assumes the credit risk associated with the accounts receivable. This provides the firm immediate access to working capital, which is important, especially if the firm has a cash flow problem. The price of factoring is determined by the creditworthiness of the firm's customer, not of the firm itself. It is also known as accounts receivable financing.

factor

A firm that purchases accounts receivable from another firm at a discount. The purchasing firm then attempts to collect the receivables.

factor

To sell accounts receivable to another party at a discount from face value. Thus, a firm in need of cash to pay down short-term debt may decide to factor its accounts receivable to another firm.

factor

  1. a firm that purchases TRADE DEBTS from client firms. See FACTORING.
  2. a firm that buys in bulk and performs a WHOLESALING function.
  3. an input (for example raw material, labour, capital) which is used to produce a good or provide a service.

factor

  1. 1a FACTOR INPUT that is used in production (see NATURAL RESOURCES, LABOUR, CAPITAL).
  2. a business that buys in bulk and performs a WHOLESALING function.
  3. a business that buys trade debts from client firms (at some agreed price below the nominal value of the debts) and then arranges to recover them for itself. See FACTOR MARKET, FACTORING.
References in periodicals archive ?
The new agreement provides Chemicon additional rights to further develop its proprietary embryonic stem cell products, Leukemia Inhibitory Factor (LIF) and ESGRO(R) into additional kits and combination products.
CHEMICON has a diverse portfolio of proprietary technologies, including a method for making fusion proteins (GST), Leukemia Inhibitory Factor (LIF), and Bioluminescence Proteins.
These products join Chemicon's extensive stem cell product portfolio that includes stem cell differentiation and characterization kits, the most extensive line of stem cell marker antibodies, and ready-to-use stem cell media and stem cell culture supplements such as ESGRO(R) and Leukemia Inhibitory Factor (LIF) - an exclusively licensed growth factor essential for the derivation and maintenance of mouse ES cells.